首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1741345

Gemigliptin市场：按药品类型、按分销管道、按最终用户、按患者人口统计、按地区

Gemigliptin Market, By Type of Drug, By Distribution Channel, By End User, By Patient Demographics, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

Gemigliptin市场规模预计在 2025 年为 19.9 亿美元，预计到 2032 年将达到 28.8 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 5.4%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	19.9亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	5.40%	2032年价值预测	28.8亿美元

Gemigliptin是一种强效选择性Dipeptidyl Peptidase-4 (DPP-4) 抑制剂，用于治疗第2型糖尿病。其独特的化学结构透过增强肠促胰岛素的作用，有效降低血糖值。这种口服药物透过促进葡萄糖依赖性胰岛素分泌和抑制升糖素释放，在血糖控制方面取得了良好的效果。作为DPP-4抑制剂类别中的一种新型药物，Gemigliptin的安全性和有效性使其成为寻求改善血糖控制和降低低血糖风险的糖尿病患者的宝贵选择。该药物独特的化学结构和作用机制使其有别于其他抗糖尿病药物。Gemigliptin通常为每日一次的口服药物，为糖尿病管理患者提供便利。然而，正在进行的研究、策略行销以及製剂和联合治疗方面的潜在创新旨在使Gemigliptin成为各种糖尿病管理环境中的宝贵选择。

市场动态：

糖尿病盛行率的上升、糖尿病认知度和诊断水平的提高以及向口服抗糖尿病药物的转变，预计将在预测期内推动全球Gemigliptin市场的成长。此外，良好的法规环境也有望在预测期内促进全球Gemigliptin市场的成长。新兴市场的扩张、联合治疗、以患者为中心的理念、儿科应用以及妊娠糖尿病预计将在预测期内为全球Gemigliptin市场带来成长机会。

然而，现有药物的竞争、专利到期、学名药的竞争以及安全问题预计将在预测期内阻碍Gemigliptin市场的成长。

本研究的主要特点

本报告对Gemigliptin市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
Gemigliptin市场的主要企业是根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行的分析。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
Gemigliptin市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
相关人员将透过用于分析Gemigliptin市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1.99 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.40%	2032 Value Projection:	USD 2.88 Bn

Gemigliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. With its unique chemical structure, gemigliptin effectively lowers blood glucose levels by enhancing the action of incretin hormones. This oral medication offers promising results in gycemic control by promoting glucose-dependent insulin secretion and suppressing glucagon release. As a newer entrant in the DPP-4 inhibitor class, Gemigliptin's safety profile and efficacy make it a valuable option for diabetes patients seeking improved glucose regulation and a reduced risk of hypoglycaemia. This medication is characterized by its unique chemical structure and mechanism of action, setting it apart from other antidiabetic drugs. Gemigliptin is typically prescribed as a once-daily oral treatment, providing convenience for patients managing their diabetes. However, ongoing research, strategic marketing, and potential innovations in formulation or combination therapies aim to position gemigliptin as a valuable option in the diverse landscape of diabetes management.

Market Dynamics:

The rising prevalence of diabetes, increasing awareness and diagnosis, and shift towards oral antidiabetic drugs are anticipated to drive growth of the global gemigliptin market over the forecast period. Moreover, a favorable regulatory environment is also expected to boost the growth of the global gemigliptin market over the forecast period. Expansion in emerging markets, combination therapies, a focus on patient-centric approaches, pediatric use, and gestational diabetes are expected to create growth opportunities for the global gemigliptin market during the forecast period.

However, competition from established drugs, patent expiry, generic competition, and safety concerns are expected to hamper growth of the gemigliptin market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the gemigliptin market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the gemigliptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Daewoong Pharmaceutical, Sanofi, LG Chem, Hanmi Pharmaceutical Co., Ltd., and Merck
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The gemigliptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the gemigliptin market

Detailed Segmentation:

Gemigliptin Market, By Type of Drug:
- Gemigliptin Monotherapy
- Gemigliptin Combination Therapy
Gemigliptin Market Segmentation, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Gemigliptin Market, By End User:
- Hospitals
- Clinics and Outpatient Facilities
- Others (Academic and Research Institutes)
Gemigliptin Market, By Patient Demographics:
- Adult Population
- Geriatric Population
Gemigliptin Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profile:
- Daewoong Pharmaceutical
- Sanofi
- LG Chem
- Hanmi Pharmaceutical Co., Ltd.
- Merck

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Gemigliptin , By Type of Drug
- Market Gemigliptin , By Distribution Channel
- Market Gemigliptin , By End User
- Market Gemigliptin , By Patient Demographics
- Market Gemigliptin , By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of diabetes
- Restraints
Competition from established drugs
- Opportunities
Expansion in emerging markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Gemigliptin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Gemigliptin Market, By Type of Drug, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Gemigliptin Monotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Gemigliptin Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Gemigliptin Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Gemigliptin Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Clinics and Outpatient Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Academic and Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Gemigliptin Market, By Patient Demographics, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Adult Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Geriatric Population
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Gemigliptin Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Drug, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Denographics, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Daewoong Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
LG Chem
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hanmi Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

11. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Gemigliptin市场：按药品类型、按分销管道、按最终用户、按患者人口统计、按地区